2024年12月13日 · Gastrointestinal stromal tumors (GISTs) treatment depends on the extent of disease and may involve surgery and/or tyrosine kinase inhibitors. Get detailed information …

As of today, five agents hold regulatory approval for the treatment of GIST: imatinib, sunitinib, regorafenib, ripretinib, and avapritinib. This, in turn, represents a success for a rare neoplasm.

This Clinical Practice Guideline provides key recommendations on the management of gastrointestinal stromal tumours. Recommendations have been agreed following a consensus …

In resectable GIST, treatment is multimodal. For tumors with a high risk of recurrence, as determined by tumor size and mitotic rate, adjuvant therapy with imatinib is indicated. In …

Surgical resection is the principal treatment for GISTs. Evaluation of the resectability of a GIST is determined by the surgeon and depends on the stage and the individual patient’s fitness for …

In a nutshell, here are the basic points about GIST treatment. Surgery to remove GIST is the first step when possible. Surgery is potentially curative for primary GISTs that have not …

2022年11月1日 · These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) …

Imatinib is the standard first-line treatment for locally advanced, inoperable and metastatic patients, except for GIST without KIT/PDGFRA mutations or with a PDGFRA exon 18 D842V …

Patients with gastrointestinal stromal tumor (GIST cancer) can receive effective treatments today. For links to experts’ treatment recommendations for GIST, see the NCCN and other expert …

STIVARGA is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with …